Related Experiment Video
Updated: May 1, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma
Keita Minami1, Rei Narimatsu1, Hajime Sasaki1
1Department of Kidney Transplant Surgery and Urology Sapporo City General Hospital Sapporo Hokkaido Japan.
Introduction:
We report a case in which enfortumab vedotin (EV) therapy was administered as a third-line treatment for locally advanced bladder cancer (bc), enabling successful radical resection.
Case Presentation:
This report describes the case of a 69-year-old male patient with locally advanced bc and pelvic lymph node (LN) metastases. After the failure of first-line chemotherapy and second-line immunotherapy, the patient received EV as third-line treatment. EV therapy resulted in significant tumor reduction, enabling successful radical cystectomy and lymph node dissection (LND). The patient remained recurrence-free for 22 months post-surgery.
Conclusion:
EV therapy suggests that it is a promising avenue for further exploration, potentially redefining the therapeutic landscape of historically challenging cases.
